Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Revenue projections:

With BIIB's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio	1.865000
forwardPE	14.082725
debtToEquity	44.329000
earningsGrowth	-0.848000
revenueGrowth	0.034000
grossMargins	0.783220
operatingMargins	0.250580
trailingEps	5.630000
forwardEps	16.520240

With a current ratio of 1.865, BIIB has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that BIIB is in a strong position to meet its immediate financial obligations without difficulty.
BIIB's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
With both earnings and revenue growth in low territory, BIIB is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
BIIB's positive gross and operating margins indicate a profitable and efficient business model. These metrics highlight the company's ability to generate income while controlling operational costs, reflecting strong financial performance.
BIIB's forward EPS being higher than its trailing EPS points to expected growth in profitability. This suggests that the company is projected to perform better in the current financial year, with higher earnings forecasted compared to the previous year.

Price projections:

Biogen Inc.'s stock price has regularly been near the lower end of projections, indicating that it may be struggling to attract investor interest. This pattern suggests a cautious sentiment surrounding the company's future performance.

Insider Transactions:

Biogen Inc. had 4 sell transactions, while the market price was at 180.24499893188477 per share.1 separate purchases of BIIB stock were made, while market price was at 195.5 per share.The insider transaction records show no compelling upward or downward trend, providing little insight into the company’s potential direction.

Recommendation changes over time:

Analysts' recent buy bias toward BIIB suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see BIIB as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.